Results 11 to 20 of about 1,678,208 (198)

Central Control of Energy Balance by Amylin and Calcitonin Receptor Agonists and Their Potential for Treatment of Metabolic Diseases [PDF]

open access: yesBasic and Clinical Pharmacology and Toxicology, 2020
AbstractThe prevalence of obesity and associated comorbidities such as type 2 diabetes and cardiovascular disease is increasing globally. Body‐weight loss reduces the risk of morbidity and mortality in obese individuals, and thus, pharmacotherapies that induce weight loss can be of great value in improving the health and well‐being of people living ...
Thomas A. Lutz   +1 more
exaly   +9 more sources

Mono and Dual Agonists of the Amylin, Calcitonin, and CGRP Receptors and Their Potential in Metabolic Diseases

open access: yesMolecular Metabolism, 2021
Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and increase weight loss efficacy in combination with current treatment options. Calcitonin gene-related peptide (CGRP)
Morten Karsdal   +2 more
exaly   +5 more sources

History of current non-insulin medications for diabetes mellitus [PDF]

open access: yesJournal of Community Hospital Internal Medicine Perspectives, 2012
This article is a brief review of the current non-insulin agents for diabetes mellitus in the United States, namely, sulfonylureas, biguanides, thiazolidinediones, meglitinides, α-glucosidase inhibitors, glucacon-like peptide-1 receptor agonists ...
Celeste C. L. Quianzon, Issam E. Cheikh
doaj   +3 more sources

Calcitonin receptor, calcitonin gene-related peptide and amylin distribution in C1/2 dorsal root ganglia

open access: yesThe Journal of Headache and Pain
Background The upper cervical dorsal root ganglia (DRG) are important for the transmission of sensory information associated with the back of the head and neck, contributing to head pain.
Tayla A. Rees   +5 more
doaj   +2 more sources

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile [PDF]

open access: yesBMC Endocrine Disorders, 2020
Abstract Background Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard. Interestingly, these molecules have several overlapping pharmacological effects, such as suppression of gastric emptying, reduction of glucagon ...
Anna Thorsø Larsen   +4 more
openaire   +3 more sources

The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist Therapy

open access: yesBiomedicines, 2022
Background: Dual Amylin and Calcitonin Receptor Agonists (DACRAs) are treatment candidates for obesity and type 2 diabetes. Recently, a once-weekly DACRA (KBP-A) showed promise, potentially due to its different exposure profile compared to daily DACRA (KBP).
Sonne, Nina   +3 more
openaire   +4 more sources

Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3Research in context

open access: yesEBioMedicine
Summary: Background: Amylin (AmyR) and calcitonin (CTR) receptor co-agonists are currently in Phase II/III clinical trials for obesity treatment. Amylin binds to a heterodimeric receptor composed of CTR and the receptor activity modifying proteins 1, 2 ...
Alexandra Oliveira Carvas   +11 more
doaj   +2 more sources

Molecular signature for receptor engagement in the metabolic peptide hormone amylin [PDF]

open access: yes, 2018
The pancreatic peptide hormone, amylin, plays a critical role in the control of appetite, and synergizes with other key metabolic hormones such as glucagon-like peptide 1 (GLP-1).
Christopher S. Walker   +47 more
core   +5 more sources

Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications. [PDF]

open access: yesJ Diabetes Investig
ABSTRACT Type 1 diabetes is defined by immune‐mediated beta‐cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension ...
Bloomgarden Z.
europepmc   +2 more sources

From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease. [PDF]

open access: yesFront Pharmacol
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver condition worldwide, reflecting the growing global burden of obesity and type 2 diabetes (T2D).
Argano C   +9 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy